Chapman, Paul

Publications

Sort by

Co-Author Network

selected publications

PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Editorial Article GET IT
Times cited: 2
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Times cited: 9
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 15
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. Journal for immunotherapy of cancer. 2021 Review GET IT
Times cited: 2
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science translational medicine. 2021 Academic Article GET IT
Times cited: 32
Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Editorial Article GET IT
Times cited: 2
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma research. 2021 Academic Article GET IT
Times cited: 12
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 15
The State of Melanoma: Emergent Challenges and Opportunities. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 27
Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia. Journal of immunotherapy (Hagerstown, Md. : 1997). 2021 Academic Article GET IT
Times cited: 3
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 5
Immune Checkpoint Inhibitor-Associated Optic Neuritis. Ophthalmology. 2020 Academic Article GET IT
Times cited: 18
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 16
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 108
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. European journal of cancer (Oxford, England : 1990). 2020 Academic Article GET IT
Times cited: 37
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of surgical oncology. 2019 Academic Article GET IT
Times cited: 28
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 7
Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 134
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. The oncologist. 2019 Letter GET IT
Times cited: 22
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF ^V600-mutated Metastatic Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 25
Elevated Levels of BRAF^V600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 1
Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain Efficacy. JCO precision oncology. 2018 Letter GET IT
Times cited: 2
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer cell. 2018 Academic Article GET IT
Times cited: 56
Chemoreduction of Orbital Recurrence of Uveal Melanoma by Intra-Arterial Melphalan. Ocular oncology and pathology. 2018 Academic Article GET IT
Times cited: 1
Changing the standard of care for treating melanoma brain metastases. The Lancet. Oncology. 2018 Comment GET IT
Times cited: 2
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 171
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer medicine. 2018 Academic Article GET IT
Times cited: 73
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet. Oncology. 2018 Academic Article GET IT
Times cited: 383
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. JAMA oncology. 2018 Academic Article GET IT
Times cited: 109
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment cell & melanoma research. 2017 Academic Article GET IT
Times cited: 36
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 161
Time to publication of oncology trials and why some trials are never published. PloS one. 2017 Academic Article GET IT
Times cited: 18
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. Oncotarget. 2017 Academic Article GET IT
Times cited: 7
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. Ophthalmology. 2017 Academic Article GET IT
Times cited: 80
PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 28
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment cell & melanoma research. 2017 Academic Article GET IT
Times cited: 30
A step forward for patients with NRAS-mutant melanoma. The Lancet. Oncology. 2017 Comment GET IT
Times cited: 1
Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017 Academic Article GET IT
Times cited: 12
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma research. 2017 Academic Article GET IT
Times cited: 33
Systemic Therapy Options for Patients With Unresectable Melanoma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2017 Review GET IT
Times cited: 7
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. Journal of the National Cancer Institute. 2016 Academic Article GET IT
Times cited: 49
Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. 2016 Academic Article GET IT
Times cited: 43
Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature medicine. 2016 Academic Article GET IT
Times cited: 29
Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. Annals of surgical oncology. 2016 Academic Article GET IT
Times cited: 35
Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases. 2016 GET IT
Times cited: 10
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma research. 2016 Academic Article GET IT
Times cited: 27
Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Review GET IT
Times cited: 5
The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Review GET IT
Times cited: 21
Reply to A. Indini et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Letter GET IT
Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 3
Osteonecrosis of the jaw a new complication related to Ipilimumab. Oral oncology. 2015 Letter GET IT
Times cited: 30
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 749
Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 15
Safety of Infusing Ipilimumab Over 30 Minutes. 2015 GET IT
Times cited: 20
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. Molecular cancer therapeutics. 2015 Academic Article GET IT
Times cited: 20
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European journal of cancer (Oxford, England : 1990). 2015 Academic Article GET IT
Times cited: 53
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. The oncologist. 2015 Academic Article GET IT
Times cited: 54
Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. Nature communications. 2015 Academic Article GET IT
Times cited: 72
Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. The New England journal of medicine. 2015 Letter GET IT
Times cited: 53
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 96
Peripheral neuropathy associated with ipilimumab: a report of 2 cases. 2015 GET IT
Times cited: 52
Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged. Cancer cell. 2014 Academic Article GET IT
Times cited: 42
Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. Cancer. 2014 Academic Article GET IT
Times cited: 16
[Not Available]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2014 Letter GET IT
Inflammatory metastatic melanoma presenting as a rash in the groin of an elderly woman. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2014 Letter GET IT
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014 Academic Article GET IT
Times cited: 324
Opportunistic infections in patients treated with immunotherapy for cancer. Journal for immunotherapy of cancer. 2014 Academic Article GET IT
Times cited: 1263
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. 2014 GET IT
Times cited: 67
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer research. 2014 Academic Article GET IT
Times cited: 228
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 809
Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. 2014 GET IT
Times cited: 34
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer journal (Sudbury, Mass.). 2014 Academic Article GET IT
Times cited: 43
Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2014 Review GET IT
Times cited: 5
Treating metastatic melanoma in 2014: what just happened and what is next?. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2014 Review GET IT
Times cited: 2
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. Journal for immunotherapy of cancer. 2013 Academic Article GET IT
Times cited: 11
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Academic Article GET IT
Times cited: 150
Dynamic prognostication using conditional survival estimates. Cancer. 2013 Academic Article GET IT
Times cited: 79
Evolutionary dynamics of cancer in response to targeted combination therapy. eLife. 2013 Academic Article GET IT
Times cited: 439
Ipilimumab for patients with advanced mucosal melanoma. The oncologist. 2013 Academic Article GET IT
Times cited: 125
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 111
Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2013 Review GET IT
Times cited: 36
Progression of RAS-mutant leukemia during RAF inhibitor treatment. 2012 GET IT
Times cited: 197
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2012 Academic Article GET IT
Times cited: 764
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Academic Article GET IT
Times cited: 1400
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England). 2012 Academic Article GET IT
Times cited: 2417
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature medicine. 2012 Academic Article GET IT
Times cited: 2722
Alan Houghton. Pigment cell & melanoma research. 2012 Academic Article GET IT
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 146
Vemurafenib sensitivity skin reaction after ipilimumab. The New England journal of medicine. 2012 Letter GET IT
Times cited: 83
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 888
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Academic Article GET IT
Times cited: 1143
Treatment of locally recurrent mucosal melanoma with topical imiquimod. 2011 GET IT
Times cited: 30
Histology and outcomes of newly detected lung lesions in melanoma patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 16
KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Academic Article GET IT
Times cited: 659
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011 Academic Article GET IT
Times cited: 6242
Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. American journal of clinical oncology. 2011 Academic Article GET IT
Times cited: 81
Therapeutic implications of the emerging molecular biology of uveal melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 93
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 63
Treatment implications of the emerging molecular classification system for melanoma. The Lancet. Oncology. 2011 Review GET IT
Times cited: 68
Inhibition of mutated BRAF in melanoma. The New England journal of medicine. 2010 Letter GET IT
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). 2010 GET IT
Times cited: 67
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010 Academic Article GET IT
Times cited: 1437
Inhibition of mutated, activated BRAF in metastatic melanoma. The New England journal of medicine. 2010 Academic Article GET IT
Times cited: 3009
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 374
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 43
Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barré syndrome. Journal of neuroscience research. 2010 Academic Article GET IT
Times cited: 22
Radiotherapy after surgical resection for head and neck mucosal melanoma. American journal of clinical oncology. 2010 Academic Article GET IT
Times cited: 54
Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 190
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010 Academic Article GET IT
Times cited: 373
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 211
Programming T cells for adoptive T cell transfer therapy. Pigment cell & melanoma research. 2010 Article GET IT
The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit? 2010 GET IT
Times cited: 2
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 24
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer immunity. 2009 Academic Article GET IT
Times cited: 79
The history and future of chemotherapy for melanoma. Hematology/oncology clinics of North America. 2009 Review GET IT
Times cited: 67
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 172
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Molecular therapy : the journal of the American Society of Gene Therapy. 2008 Academic Article GET IT
Times cited: 75
Combining a peptide vaccine with high-dose interleukin-2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Editorial Article GET IT
Times cited: 5
Phase II study of extended-dose temozolomide in patients with melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 58
Antibody response to GD3 ganglioside is independent of NKT cells. Cytotherapy. 2008 Academic Article GET IT
Times cited: 1
Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand. Immunology. 2008 Academic Article GET IT
Times cited: 43
Melanoma vaccines. Seminars in oncology. 2007 Review GET IT
Times cited: 18
Detection of melanoma cells in sentinel lymph nodes by PCR is not yet ready for prime time. Pigment cell research. 2007 Article GET IT
Times cited: 2
Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Molecular therapy : the journal of the American Society of Gene Therapy. 2007 Academic Article GET IT
Times cited: 86
Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. The Journal of molecular diagnostics : JMD. 2007 Academic Article GET IT
Times cited: 30
When you look matters: the effect of assessment schedule on progression-free survival. Journal of the National Cancer Institute. 2007 Academic Article GET IT
Times cited: 145
Adjuvant therapy of melanoma. Cancer journal (Sudbury, Mass.). 2007 Review GET IT
Times cited: 28
Immunotherapy of melanoma. Hematology/oncology clinics of North America. 2006 Review GET IT
Times cited: 14
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer. 2006 Academic Article GET IT
Times cited: 46
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. Journal of immunotherapy (Hagerstown, Md. : 1997). 2006 Academic Article GET IT
Times cited: 22
Variates of survival in metastatic uveal melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 233
Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b. The oncologist. 2005 Review GET IT
Times cited: 11
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 194
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer. 2005 Academic Article GET IT
Times cited: 93
Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses. Cancer chemotherapy and biological response modifiers. 2005 Review GET IT
Times cited: 5
Clinical significance of BRAF mutations in metastatic melanoma. Journal of translational medicine. 2004 Academic Article GET IT
Times cited: 259
T-cell chauvinists versus antibody advocates--can't we all just get along?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Editorial Article GET IT
Times cited: 4
A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine. 2004 Academic Article GET IT
Times cited: 27
Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 60
Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma. 2004 GET IT
Times cited: 29
Defining adequate surgery for primary melanoma. The New England journal of medicine. 2004 Editorial Article GET IT
Times cited: 19
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 227
Counterpoint: The case against adjuvant high-dose interferon-alpha for melanoma patients. Journal of the National Comprehensive Cancer Network : JNCCN. 2004 Academic Article GET IT
Times cited: 5
Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 104
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 137
Cross-presentation of disialoganglioside GD3 to natural killer T cells. The Journal of experimental medicine. 2003 Academic Article GET IT
Times cited: 243
Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Current opinion in investigational drugs (London, England : 2000). 2003 Review GET IT
Times cited: 36
Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma research. 2003 Academic Article GET IT
Times cited: 31
How can we tell when cancer vaccines vaccinate?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Editorial Article GET IT
Times cited: 8
Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients. Cytokines, cellular & molecular therapy. 2002 Academic Article GET IT
Times cited: 2
Vaccinating patients with autologous tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Editorial Article GET IT
Times cited: 3
An optimal two-stage phase II design utilizing complete and partial response information separately. Controlled clinical trials. 2002 Academic Article GET IT
Times cited: 23
Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma research. 2002 Academic Article GET IT
Times cited: 11
Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Letter GET IT
Times cited: 5
Perk up your PREP. Nursing times. 2002 Academic Article GET IT
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 71
T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 97
Immunotherapy of melanoma. Cancer chemotherapy and biological response modifiers. 2002 Review GET IT
Times cited: 1
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 127
Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 33
Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 53
Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. International journal of cancer. 2000 Academic Article GET IT
Times cited: 100
Systemic chemotherapy. Clinics in plastic surgery. 2000 Review GET IT
Times cited: 14
Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 106
Prophylactic recombinant epoetin alfa markedly reduces the need for blood transfusion in patients with metastatic melanoma treated with biochemotherapy. Cytokines, cellular & molecular therapy. 1999 Academic Article GET IT
Times cited: 8
Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines, cellular & molecular therapy. 1999 Academic Article GET IT
Times cited: 42
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 655
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 167
The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains. The Journal of biological chemistry. 1999 Academic Article GET IT
Times cited: 35
Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 52
Phase I study of R24 in patients with metastatic melanoma including evaluation of immunologic parameters. Cancer biotherapy & radiopharmaceuticals. 1998 Academic Article GET IT
Times cited: 10
Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma research. 1997 Review GET IT
Times cited: 70
Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997 Academic Article GET IT
Times cited: 35
Medical treatment of metastatic melanoma. The Surgical clinics of North America. 1996 Review GET IT
Times cited: 20
Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen. Journal of immunology (Baltimore, Md. : 1950). 1996 Academic Article GET IT
Times cited: 24
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clinical cancer research : an official journal of the American Association for Cancer Research. 1996 Academic Article GET IT
Times cited: 96
Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1996 Academic Article GET IT
Times cited: 19
Anti-idiotypic monoclonal antibody cancer vaccines. Seminars in cancer biology. 1995 Review GET IT
Times cited: 6
A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer. 1995 Academic Article GET IT
Times cited: 47
Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. International journal of cancer. 1995 Academic Article GET IT
Times cited: 49
Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. Journal of immunology (Baltimore, Md. : 1950). 1995 Academic Article GET IT
Times cited: 63
Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody. Cancer immunology, immunotherapy : CII. 1994 Academic Article GET IT
Times cited: 11
Combination chemotherapy for metastatic melanoma: the importance of tamoxifen. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Letter GET IT
Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 1994 Academic Article GET IT
Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood. 1994 Academic Article GET IT
Times cited: 49
Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993 Academic Article GET IT
Times cited: 218
Non-antibody immunotherapy of cancer. Current opinion in immunology. 1993 Review GET IT
Times cited: 20
Recognition of autoantigens by patients with melanoma. Annals of the New York Academy of Sciences. 1993 Review GET IT
Times cited: 15
Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma research. 1992 Academic Article GET IT
Times cited: 41
A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. Cancer. 1991 Academic Article GET IT
Times cited: 29
Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. The Journal of clinical investigation. 1991 Academic Article GET IT
Times cited: 64
Phase II trial of cisplatin and etoposide in patients with metastatic melanoma. Investigational new drugs. 1991 Academic Article GET IT
Times cited: 2
Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer research. 1990 Academic Article GET IT
Times cited: 83
Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside. Journal of immunology (Baltimore, Md. : 1950). 1990 Academic Article GET IT
Times cited: 36
Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity. Cancer research. 1990 Academic Article GET IT
Times cited: 37
Treatment of human metastatic melanoma with mouse monoclonal antibodies against GD3 ganglioside. Progress in clinical and biological research. 1989 Academic Article GET IT
Times cited: 9
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. Investigational new drugs. 1988 Academic Article GET IT
Times cited: 29
Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1987 Academic Article GET IT
Times cited: 202
Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. Journal of immunology (Baltimore, Md. : 1950). 1987 Academic Article GET IT
Times cited: 118
Synthesis of acetylated human fetal hemoglobin. The Journal of biological chemistry. 1981 Academic Article GET IT
Times cited: 11

more ...

less ...

Background

education and training

M.D., Cornell University Medical College 1981
B.A., Cornell University 1977

Contact

full name

Paul Chapman

VIVO Weill Cornell Medical College

Paul Chapman Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name